A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization

Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2016

At a glance

  • Drugs Lacosamide (Primary) ; Antiepileptic drugs
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors UCB Pharma SA
  • Most Recent Events

    • 04 Jul 2016 According to an Daiichi Sankyo media release, the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for Lacosamide (VIMPAT) as an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adult patients with epilepsy who have not obtained sufficient response to other antiepileptic drugs.
    • 21 Dec 2015 Results of this trial were presented at the 2015 Annual Meeting of the American Epilepsy Society, according to a Daiichi Sankyo media release.
    • 21 Dec 2015 Results published in a Daiichi Sankyo media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top